With an increasing demand for health economics and HTAs in Europe and for us to continue co-creating and delivering results together with our clients, we are extremely thrilled to announce that we will be expanding our physical presence with a highly skilled team and a new office in Stockholm, Sweden. A stronger presence in Sweden, will enable us to follow the demand and continue to serve our clients with their needs in line with our company’s DNA.
Related to this, we are very pleased to welcome Thomas Kristensen to our team! Thomas recently joined us as a Senior Director and will be managing NHTA in Sweden.
Thomas is an experienced health economist with more than 10 years’ experience in various Nordic and Global HEOR and market access roles. Most recently Thomas worked as a Global Health Economics Director in Takeda leading the development and implementation of global health economic strategies including value assessments, advisory boards, early and late stage HE models etc. for the Neuroscience pipeline. Prior to that, he successfully led value demonstration, access and HE-related activities within rare diseases, CV and asthma in the Nordics, such as access strategies, HTA submissions, model adaptations, RWE generation, payer tools, price negotiations, and innovative pricing/contracting while working at Takeda Sweden, Shire Nordics and AstraZeneca Nordic-Baltic.
Thomas holds a MSc in Medical Market Access and a BSc in Medicine with Industrial Specialization from Aalborg University, Denmark.
Please do not hesitate to reach out to Thomas: tk@nhta.com